Border Collies are celebrated for their high intelligence, agility, and outstanding working abilities. They remain a favorite for herding enthusiasts as well as active family pets across the United States. Yet like many dog breeds, Border Collies are vulnerable to inheritable health concerns, notably glaucoma coupled with goniodysgenesis (GGD), which is a serious eye disorder that can ultimately cause blindness.
Across the U.S., conscientious breeders now actively utilize DNA testing to detect glaucoma and goniodysgenesis predisposition, identifying carrier and affected dogs. This vital testing prevents breeding that could pass on these painful eye ailments and helps ensure better breed health.
Goniodysgenesis refers to improper development of the drainage angle in the eye's anterior chamber. This malformation blocks proper fluid drainage, increasing intraocular pressure. The resulting pressure damages the optic nerve, leading to glaucoma, a condition often causing discomfort and irreversible vision loss.
Common symptoms in affected dogs include watery eyes, sensitivity to light, apparent eye pain, unusual eye movements, and dilated pupils. Early recognition of signs is key to slowing disease progression.
Recent research (2025) has pinpointed a mutation in the OLFML3 gene strongly linked to severe goniodysgenesis and early glaucoma onset in Border Collies. This mutation follows an autosomal recessive inheritance pattern, which means a dog must inherit two copies of the faulty gene—one from each parent—to be at high risk.
The mutated OLFML3 gene is passed down through families in accordance with autosomal recessive genetics. Possible outcomes when breeding dogs with different genetic statuses are:
Understanding these inheritance patterns empowers breeders to make informed genetic choices to reduce the disease’s presence in the breed through DNA screening before breeding.
DNA samples in the U.S. are typically collected via cheek swabs or blood draws, easily performed by veterinarians or trained technicians. These samples are sent to accredited American laboratories such as Animal Genetics or Wisdom Panel, which test for the OLFML3 gene mutation.
The test categorizes dogs as clear (no mutation), carriers (one copy), or affected (two copies). Breeders combine these genetic insights with comprehensive eye exams performed by board-certified veterinary ophthalmologists to avoid producing affected puppies.
Standard breeding guidelines to minimize glaucoma and goniodysgenesis include:
Such strategies are critical for supporting lifelong eye health and reducing the incidence of GGD in American Border Collies.
For American Border Collie breeders, glaucoma and goniodysgenesis DNA testing focusing on the OLFML3 gene mutation is an indispensable tool in 2025. Alongside ophthalmologic screenings and thoughtful mating decisions, this testing helps mitigate this painful hereditary disease, enhancing the wellbeing of these beloved herding dogs.
Those seeking Border Collie puppies in the U.S. should prioritize working with reputable breeders who conduct thorough health screenings, including GGD DNA testing, to ensure healthier, happier companions for the future.